# TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment

> **NCT02711813** · PHASE2 · TERMINATED · sponsor: **Theramab LLC** · enrollment: 60 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** TAB08
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02711813
- **Lead sponsor:** Theramab LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Administrative reasons
- **Last updated:** 2018-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711813, "TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02711813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*